Abstract 2281: AZD4241, an orally bioavailable ERα PROTAC, degrades wild-type and mutant ERα and delivers anti-tumour activity in preclinical breast cancer models

芳香化酶 癌症研究 富维斯特朗 雌激素受体α 雌激素受体 乳腺癌 平方毫米 突变体 受体 癌症 药理学 医学 雌激素 细胞培养 癌细胞 化学 细胞 生物 雌激素受体 核受体 体内 选择性雌激素受体调节剂 细胞生长 生物利用度 三苯氧胺 内科学
作者
Mandy Lawson,Natalie Cureton,Lynet Nyoni,Sophie D’Arcy,Lydia M. Parkinson,Ana Quiroga,Pablo Morentin Gutierrez,Ji Li,Hana Baakza,Thomas G. Hayhow,Claire Crafter,Lucy Ireland,Gemma Hardman Fowler,Georgia M. Simmons,Laki Buluwela,Simak Ali,Neil J. Gibson
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 2281-2281
标识
DOI:10.1158/1538-7445.am2026-2281
摘要

Abstract Estrogen receptor alpha (ERα) is a member of the nuclear hormone receptor superfamily and a key driver of hormone receptor-positive (HR+) breast cancer. Current ER-pathway inhibitors include aromatase inhibitors (letrozole, anastrozole, exemestane), selective estrogen receptor modulators (SERMs; tamoxifen), and selective estrogen receptor degraders (SERDs; fulvestrant, elacestrant, imlunestrant). In metastatic ER-positive disease, resistance is common and often involves the emergence of ESR1 mutations (e.g., Y537S, D538G). These mutations occur in the ligand-binding domain of ERα and enable ligand-independent ER activation, reducing the effectiveness of aromatase inhibitors and some antagonists. This underscores the need for novel treatments that target ER in both wild-type (ESR1wt) and mutant (ESR1m) settings, including more effective ERα degraders, as demonstrated clinically by SERDs. Here we characterise AZD4241, a novel ER-targeting proteolysis targeting chimera (PROTAC), that degrades both wt and mutant ERα and delivers anti-tumour efficacy in preclinical breast cancer models. AZD4241 degraded ERα in ESR1wt cell lines (IC50 0.4 nM in MCF7 cells) and showed good oral bioavailability across species. ERα half-life was reduced through PROTAC-mediated degradation requiring cereblon engagement and proteasomal activity. In MCF7 cells engineered to express clinically relevant ESR1 mutations, AZD4241 reduced ERα with degradation potency (IC50 0.2-1.0 nM) comparable to ESR1wt controls. AZD4241 completely inhibited estradiol-induced gene expression (e.g., GREB1, PGR, and TFF1) and suppressed proliferation of ER-dependent breast cancer cell lines with low-nanomolar IC50 values. In vivo, AZD4241 induced dose-dependent anti-tumour activity and, in some cases, tumour regressions across ESR1wt and ESR1m patient-derived xenograft (PDX) models, including a palbociclib-resistant model. Efficacy was associated with marked reductions in ERα protein levels and decreased ER pathway activity, supporting a pharmacodynamic link between target degradation, suppression of ER signalling and efficacy. Collectively, these data confirm that AZD4241 is a potent, orally bioavailable degrader of wt and mutant ERα, driving anti-tumour efficacy in ESR1wt, ESR1m, and CDK4/6 inhibitor-resistant PDX models. These findings support the use of AZD4241 as a novel ER-PROTAC with potential to overcome key resistance mechanisms to current standards of care and deliver clinical benefit for patients with ER-positive breast cancer. Citation Format: Mandy Lawson, Natalie Cureton, Lynet Nyoni, Sophie D’Arcy, Lydia Parkinson, Ana Quiroga, Pablo Morentin Gutierrez, Ji Li, Hana Baakza, Thomas Hayhow, Claire Crafter, Lucy Ireland, Gemma Hardman Fowler, Georgia M. Simmons, Lakjaya Buluwela, Simak Ali, Neil Gibson. AZD4241, an orally bioavailable ERα PROTAC, degrades wild-type and mutant ERα and delivers anti-tumour activity in preclinical breast cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2281.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Arthur发布了新的文献求助10
刚刚
吴文章完成签到 ,获得积分10
1秒前
HanruiWang完成签到,获得积分10
1秒前
1111111111111发布了新的文献求助10
2秒前
景行完成签到 ,获得积分10
2秒前
尼古丁真的应助被Jing采纳,获得10
2秒前
ssslllppp完成签到,获得积分10
2秒前
shadow完成签到,获得积分10
3秒前
dinghongmei完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
Cutecutely关注了科研通微信公众号
5秒前
5秒前
5秒前
5秒前
YFFS完成签到,获得积分10
7秒前
1111111111111完成签到,获得积分10
8秒前
泉er完成签到 ,获得积分10
8秒前
TT完成签到,获得积分10
8秒前
8秒前
9秒前
科研狗完成签到,获得积分20
9秒前
9秒前
9秒前
9秒前
10秒前
11秒前
yu发布了新的文献求助10
11秒前
bea发布了新的文献求助30
11秒前
11秒前
怡然的向南完成签到,获得积分10
12秒前
tt发布了新的文献求助10
12秒前
星辰大海的应助被崖林采纳,获得10
13秒前
小衫生发布了新的文献求助10
13秒前
唐陌发布了新的文献求助10
14秒前
哈基米发布了新的文献求助20
15秒前
啊哈哈哈哈完成签到 ,获得积分10
16秒前
16秒前
无私的起眸完成签到,获得积分20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153442
求助须知:如何正确求助?哪些是违规求助? 9550127
关于积分的说明 21696715
捐赠科研通 7741908
什么是DOI,文献DOI怎么找? 3425483
关于科研通互助平台的介绍 2550608
邀请新用户注册赠送积分活动 2469152